Triphase Accelerator Corporation, a Toronto-based drug development company, announced that the U.S. FDA granted orphan drug designation for marizomib for the treatment of patients with malignant glioma, an aggressive form of brain cancer with a significant unmet need due to its poor prognosis.  Marizomib is a novel, irreversible, potent and brain-penetrant proteasome inhibitor which inhibits all three proteasome subunits, thus providing superior potency, specificity, and duration of proteasome inhibition.  Triphase is evaluating marizomib in combination with bevacizumab in patients with recurrent glioblastoma.  The company is developing marizomib in both intravenous (IV) and oral formulations as a potential best-in-class proteasome inhibitor for hematologic malignancies and solid tumors.